Pharma sector calls for drug prices to build in real-world value

The pharmaceutical industry wants future negotiations on drug pricing to include the extent to which drugs prevent costly hospital stays and details of other societal benefits they generate

Susan Mitchell

Deputy Editor and Health Editor @susmitchellsbp
17th November, 2019
Aidan Lynch: the IPHA president believes price needs to be looked at as an end-to-end cost rather than in isolation Pic: Bryan Meade

The pharmaceutical industry wants future negotiations on drug pricing to include the extent to which drugs prevent costly hospital stays and details of other societal benefits they generate.

Aidan Lynch, general manager of GSK and president of the Irish Pharmaceutical Healthcare Association (IPHA), which represents the industry, said: “If we could look, not just at price in isolation, but at an end-to-end cost, such as bed days and reduced staff required – that type of...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month, €19.99 Monthly thereafter

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Some people with cystic fibrosis still awaiting Covid-19 vaccine, charity warns

Health Donal MacNamee 3 days ago

Top medic: ‘If the state can pay for Viagra, it can pay for extreme pregnancy sickness drugs’

Health Daniel Murray 1 week ago

Over 300 administered vaccine doses not recorded as given to priority groups

Health Rachel Lavin 1 week ago

Praxis Care to hire 400 new carers as demand for services grows